IceCure Medical Soars 200% After 70% U.S. ProSense Install Surge
ICCM•IceCure Medical shares jumped over 200% Wednesday to post their largest one-day gain since August 2021 after the company reported a 70% increase in its active U.S. ProSense install base since FDA cleared the system in October 2025. All three covering analysts rate the stock as Buy.
1. Stock Performance
IceCure Medical shares exploded over 200% in a single session, marking the strongest one-day advance since August 2021. The surge reflects heightened investor enthusiasm as the company’s flagship ProSense system gains commercial momentum.
2. ProSense Adoption
The active U.S. install base of ProSense breast cancer cryoablation systems climbed 70% since FDA marketing authorization in October 2025. New units have been deployed across major healthcare centers in Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix and Memphis.
3. FDA Authorization and Clinical Use
ProSense is the first FDA-authorized device for localized treatment of low-risk breast cancer in women aged 70 and older when combined with hormone therapy. The minimally invasive system freezes tumors with liquid nitrogen in an office setting, offering faster recovery and fewer complications than surgery.
4. Analyst Sentiment
All three analysts covering IceCure Medical maintain Buy ratings, with an average price target of $44.50, implying nearly 2,000% upside from the most recent closing price. Retail sentiment has swung from bearish to extremely bullish, driving record trading volume.
